Search

Displaying results 2521 - 2530 of 10000 in total
  1. Drug

    Bevacizumab

    go.drugbank.com/drugs/DB00112
    ApprovedInvestigational

    There is a great deal of evidence indicating that vascular endothelial growth factor (VEGF) is important for the survival and proliferation of cancer cells. … [A192834,A192888,A192837,A192891,A192894] Bevacizumab is a humanized monoclonal IgG antibody that inhibits angiogenesis by binding and neutralizing VEGF-A.

    Synonyms: 贝伐珠单抗International brands: Ai Rui Tuo, 安倍斯
  2. Drug

    Beroctocog alfa

    go.drugbank.com/drugs/DB14473
    ApprovedInvestigational

    Mixtures: OPTIVATE(R), HAEMATE PProducts: DRIED FACTOR VIII FRACTION 500 UI + FACTOR DE VON WILLEBRAND 800 UI, FACTOR VIII DE COAGULACION HUMANO 500 UI
  3. Drug

    Difluocortolone

    go.drugbank.com/drugs/DB09095
    ApprovedWithdrawn

    Difluocortolone is a potent topical corticosteroid. It is commonly used in dermatology for the reduction of inflammation and itching.

    Mixtures: İZOSOL S % 1 + % 0,1 KREM, TİNAGEN 1 MG+10 MG/1 G DERİ KREMİ, 15 GCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Inducers
  4. Drug

    Dacomitinib

    go.drugbank.com/drugs/DB11963
    ApprovedInvestigational

    Dacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible

    Categories: Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index, P-glycoprotein substrates with a Narrow Therapeutic Index
  5. Drug

    Oxaliplatin

    go.drugbank.com/drugs/DB00526
    ApprovedInvestigational

    Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. … [A797] Oxaliplatin was approved by the FDA on January 9, 2004 and is currently marketed by Sanofi-Aventis under the trademark Eloxatin®.[L47316]

    Categories: OCT2 Substrates with a Narrow Therapeutic IndexSynonyms: (SP-4-2-(1R-TRANS))-(1,2-CYCLOHEXANEDIAMINE-N,N')(ETHANEDIOATO(2-)-O,O')PLATINUM, PLATINUM, ((1R,2R)-1,2-CYCLOHEXANEDIAMINE-.KAPPA.N,.KAPPA.N')(ETHANEDIOATO(2-)-.KAPPA.O1,.KAPPA.O2)-, (SP-4-2)-
  6. Drug

    Tenofovir alafenamide

    go.drugbank.com/drugs/DB09299
    ApprovedInvestigational

    [A178327] Tenofovir alafenamide is indicated to treat chronic hepatitis B,[L6241] treat HIV-1,[L4388,L6277,L6280,L6283] and prevent HIV-1 infections. … Tenofovir alafenamide is a novel [tenofovir] prodrug developed in order to improve renal safety when compared to the counterpart [tenofovir disoproxil].

    Mixtures: GENVOYA ® TABLETAS RECUBIERTAS, DESCOVY® 200MG/10MG TABLETAS RECUBIERTASCategories: Vitamin B Complex, Cytochrome P-450 Substrates
  7. Drug

    Busulfan

    go.drugbank.com/drugs/DB01008
    ApprovedInvestigational

    Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. … According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.

    Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 SubstratesSynonyms: 1, 4-Bis[methanesulfonoxy]butane
  8. Drug

    Tedizolid

    go.drugbank.com/drugs/DB14569
    ApprovedInvestigational

    This product is currently available as both an oral tablet and as a powder for intravenous injection.[L11232] … [A199086, A199131] Tedizolid is a member of the oxazolidinone class of antibiotics, which includes the previously approved [linezolid] and is generally effective against multidrug-resistant Gram-positive

    Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates, Heterocyclic Compounds, 1-Ring
  9. Drug

    Miglustat

    go.drugbank.com/drugs/DB00419
    ApprovedInvestigational

    Miglustat is now the first and only approved therapy for patients with Niemann-Pick disease type C (NP-C). … Miglustat, commonly marketed under the trade name Zavesca, is a drug used to treat Gaucher disease.

    Categories: Heterocyclic Compounds, 1-RingSynonyms: N-(n-Butyl)deoxynojirimycin, N-butyl-1-deoxynojirimycin
  10. Drug

    Evinacumab

    go.drugbank.com/drugs/DB15354
    ApprovedInvestigational

    Evinacumab is a recombinant human IgG4 monoclonal antibody targeted against angiopoietin-like protein 3 (ANGPTL3) and the first drug of its kind. … Evinacumab is novel in its mechanism of action compared with other lipid-lowering therapies and therefore provides a unique and synergistic therapeutic option in the treatment of HoFH.

    Categories: Angiopoietin-like 3 Inhibitor, Angiopoietin-like 3 Inhibitors